WeLeader Biomedical Co., Ltd.

7713 · TWO · Healthcare / Medical Devices

70.60TWD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close70.60

Open70.60

Day Range70.60 – 70.60

52-Week Range63.17 – 76.58

Volume1.20K

Market Cap3.38B

P/E (TTM)13.84

Forward P/E0.00

EPS5.37

Dividend Yield5.52%

Beta0.06

50-Day Avg72.44

200-Day Avg70.76

About

WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system. The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical immune assay products, TTA automated pre-processing products, POCT central laboratory products, and CCM fully automated track processing products. It serves research institutions, schools, hospitals, laboratories, and hospitals. The company was founded in 1992 and is headquartered in Kaohsiung, Taiwan.

Company Details

SectorHealthcare
IndustryMedical Devices
CEOChen Hung-Jen
Employees0
HeadquartersNo. 80, Minzu 1st Road, Kaohsiung, Taiwan, Taiwan
Websitehttps://www.weleader.com.tw

Leadership

Chen Hung-JenPresident
Lo Chun-IAccounting Manager

Financials

Income Statement

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	841.14M	1.04B	940.70M	991.13M	1.11B
Growth (%)	-	+23.13%	-9.17%	+5.36%	+11.92%
Cost of Revenue	622.22M	743.97M	642.62M	674.80M	738.33M
Gross Profit	218.92M	291.75M	298.08M	316.32M	370.97M
Gross Margin	26.03%	28.17%	31.69%	31.92%	33.44%
Operating Expense	86.26M	97.64M	100.59M	102.13M	109.84M
Operating Income	132.66M	194.11M	197.49M	214.20M	261.13M
Operating Margin	15.77%	18.74%	20.99%	21.61%	23.54%
EBITDA	-	306.57M	303.04M	329.59M	393.16M
EBITDA Margin	-	29.60%	32.21%	33.25%	35.44%
Net Income	105.77M	153.80M	152.28M	170.21M	208.56M
Net Income Margin	12.57%	14.85%	16.19%	17.17%	18.80%
R&D	0	-	-	-	-
R&D as % of Total Revenue	0.00%	-	-	-	-
Interest Expense	6.16M	4.21M	5.69M	5.80M	8.02M
Interest Expense % of Total Revenue	0.73%	0.41%	0.61%	0.58%	0.72%

Balance Sheet

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	883.09M	1.60B	1.73B	2.00B	2.45B
Total Liabilities	525.67M	954.19M	881.78M	1.09B	1.19B
Total Equity	357.41M	646.30M	845.78M	908.47M	1.26B
Cash	111.52M	100.73M	94.69M	174.97M	237.71M
Net Debt	-	305.55M	228.31M	320.43M	262.27M

Cash Flow

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	238.03M	280.27M	231.86M	278.76M	313.30M
Capital Expenditure	23.89M	661.65M	115.73M	174.27M	213.74M
Free Cash Flow	214.13M	-381.38M	116.13M	104.50M	99.55M
Dividends Paid	22.36M	9.77M	29.75M	95.63M	153.17M
FCF to OCF	89.96%	-136.08%	50.09%	37.49%	31.78%
Dividend Paid to FCF	10.44%	-2.56%	25.62%	91.52%	153.86%

Key Statistics & Ratios

Market Cap3.38B

Enterprise Value4.15B

Trailing P/E13.84

Forward P/E0.00

Price / Sales2.79

Price / Book2.80

EPS5.37

Book Value26.40

Revenue (TTM)1.21B

Gross Profit (TTM)424.28M

EBITDA339.71M

Profit Margin20.61%

Operating Margin26.96%

Return on Equity21.80%

Return on Assets8.34%

Shares Outstanding45.48M

Shares Float8.14M

Beta0.06

Dividend Yield5.52%

Dividend Rate4.10

Payout Ratio76.28%

Dividends

20261×

4.10Mar 27, 2026

20251×

3.37Jun 3, 2025

20241×

2.30Jun 13, 2024